These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34286555)

  • 21. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome and stone disease.
    Soligo M; Morlacco A; Zattoni F; Valotto C; DE Giorgi G; Beltrami P
    Panminerva Med; 2022 Sep; 64(3):344-358. PubMed ID: 34609121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of nephrolithiasis with hypertension and obesity: a review.
    Obligado SH; Goldfarb DS
    Am J Hypertens; 2008 Mar; 21(3):257-64. PubMed ID: 18219300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stone formation in patients less than 20 years of age is associated with higher rates of stone recurrence: Results from the Registry for Stones of the Kidney and Ureter (ReSKU).
    Li Y; Bayne D; Wiener S; Ahn J; Stoller M; Chi T
    J Pediatr Urol; 2020 Jun; 16(3):373.e1-373.e6. PubMed ID: 32280060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic Disorders in Patients with Nephrolithiasis in Iran.
    Shahidi S; Ghasemi G
    Iran J Kidney Dis; 2022 Jan; 1(1):1-5. PubMed ID: 35271494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do Overweight and Obese Pediatric Stone Formers Have Differences in Metabolic Abnormalities Compared With Normal-weight Stone Formers?
    Cambareri GM; Giel DW; Bayne AP; Corbett S; Schurtz E; Kovacevic L; Sukhu T; Yap M; Chiang G
    Urology; 2017 Mar; 101():26-30. PubMed ID: 27641936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and biochemical profile of patients with "pure" uric acid nephrolithiasis compared with "pure" calcium oxalate stone formers.
    Negri AL; Spivacow R; Del Valle E; Pinduli I; Marino A; Fradinger E; Zanchetta JR
    Urol Res; 2007 Oct; 35(5):247-51. PubMed ID: 17786420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metabolic syndrome and nephrolithiasis].
    Kohjimoto Y; Iba A; Sasaki Y; Hara I
    Hinyokika Kiyo; 2011 Jan; 57(1):43-7. PubMed ID: 21304261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes.
    Bobulescu IA; Maalouf NM; Capolongo G; Adams-Huet B; Rosenthal TR; Moe OW; Sakhaee K
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1498-503. PubMed ID: 24026180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?
    Khan SR
    Urol Res; 2012 Apr; 40(2):95-112. PubMed ID: 22213019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
    Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
    J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized Intervention in Monogenic Stone Formers.
    Policastro LJ; Saggi SJ; Goldfarb DS; Weiss JP
    J Urol; 2018 Mar; 199(3):623-632. PubMed ID: 29061541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrolithiasis in Israel: Epidemiological Characteristics of Return Patients in a Tertiary Care Center.
    Abu-Ghanem Y; Kleinmann N; Winkler HZ; Zilberman DE
    Isr Med Assoc J; 2016 Dec; 18(12):725-728. PubMed ID: 28457074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic kidney disease in kidney stone formers.
    Rule AD; Krambeck AE; Lieske JC
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):2069-75. PubMed ID: 21784825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrolithiasis-related end stage renal disease.
    Pipili C; Kiriakoutzik I; Petychaki F; Koutsovasili A
    Minerva Urol Nefrol; 2013 Jun; 65(2):101-7. PubMed ID: 23703097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The changing profile of patients with calcium nephrolithiasis and the ascendancy of overweight and obesity: a comparison of two patient series observed 25 years apart.
    Rendina D; De Filippo G; De Pascale F; Zampa G; Muscariello R; De Palma D; Ippolito R; Strazzullo P
    Nephrol Dial Transplant; 2013 Nov; 28 Suppl 4():iv146-51. PubMed ID: 23595293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing in gender prevalence of nephrolithiasis.
    Cicerello E; Mangano MS; Cova G; Ciaccia M
    Urologia; 2021 May; 88(2):90-93. PubMed ID: 33084513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal stone disease and obesity: what is important for urologists and nephrologists?
    Ahmed MH; Ahmed HT; Khalil AA
    Ren Fail; 2012; 34(10):1348-54. PubMed ID: 23013150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?
    Mirheydar HS; Banapour P; Massoudi R; Palazzi KL; Jabaji R; Reid EG; Millard FE; Kane CJ; Sur RL
    Int Braz J Urol; 2014; 40(6):772-80. PubMed ID: 25615245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetics of kidney stone disease.
    Howles SA; Thakker RV
    Nat Rev Urol; 2020 Jul; 17(7):407-421. PubMed ID: 32533118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.